. Author manuscript; available in PMC: 2022 May 1.

Published in final edited form as: Transplant Cell Ther. 2021 Feb 26;27(5):410–422. doi: 10.1016/j.jtct.2021.02.030

Table 5.

Comparisons between original HCT-CI and eGFR-based HCT-CI for prediction of non-relapse mortality (NRM) and overall survival (OS) in the training and validation set

Outcomes	Original HCT-CI	eGFR-based HCT-CI
Non-relapse mortality
c-statistics training set (entire cohort) N=8102	0.6774	0.6801
c-statistics validation set (entire cohort) N= 5403	0.6791	0.6823
c-statistics training set (subset with renal dysfunction^*) N=4237	0.6735	0.6761
c-statistics validation set (subset with renal dysfunction^*) N=2825	0.6805	0.6855
Overall survival
c-statistics training set (entire cohort) N=8102	0.6251	0.6252
c-statistics validation set (entire cohort) N= 5403	0.6277	0.6289
c-statistics training set (subset with renal dysfunction^*) N=4237	0.6225	0.6242
c-statistics validation set (subset with renal dysfunction^*) N=2825	0.6339	0.6379

Renal dysfunction is defined as estimated glomerular filtration rate (eGFR) ≤ 89.

Note: There was no statistically significant differences between original HCT-CI and eGFR-based eGFR.